Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.

Am J Physiol Renal Physiol

Ambulatory Nephrology Unit, Rambam-Health Care Campus, Faculty of Medicine, Technion, Haifa 31096, Israel.

Published: March 2008

AI Article Synopsis

Article Abstract

Nephrotic syndrome (NS) is a clinical state characterized by massive proteinuria and edema. It is believed that nephrin and podocin are involved in the development of proteinuria. The proteinuria and effects of eplerenone alone or combined with enalapril on nephrin/podocin abundance in rats with NS have not yet been studied. Therefore, the present study was designed to examine the early (beginning 2 days before NS induction) and late (beginning 2 wk after NS induction) effects of eplerenone and enalapril, alone or combined, on proteinuria and nephrin/podocin abundance in rats with adriamycin-induced NS. Adriamycin caused a significant increase in daily protein excretion (U(pr)V; from 26.96 +/- 3.43 to 958.57 +/- 56.7 mg/day, P < 0.001) and cumulative proteinuria [from 900.33 +/- 135.5 to 22,490.62 +/- 931.26 mg (P < 0.001)] during 6 wk. Early treatment with enalapril significantly decreased U(pr)V from 958.6 +/- 56.7 to 600.31 +/- 65.13 mg/day (P < 0.001) and cumulative proteinuria to 12,842.37 +/- 1,798.17 mg/6 wk (P < 0.001). Similarly, early treatment with eplerenone produced a profound antiproteinuric effect: U(pr)V decreased from 958.57 +/- 56.7 to 593.38 +/- 21.83 mg/day, P < 0.001, and cumulative proteinuria to 16,601.84 +/- 1,334.31 mg/6 wk; P < 0.001. An additive effect was obtained when enalapril and eplerenone were combined: U(pr)V decreased from 958.57 +/- 56.69 to 424.17 +/- 38.54 mg/day, P < 0.001, and cumulative protein excretion declined to 10,252.88 +/- 1,011.3 mg/6 wk, P < 0.001. These antiproteinuric effects were associated with substantial preservation of glomerular nephrin and podocin. In contrast, late treatment with either enalapril or eplerenone alone or combined mildly decreased U(pr)V and cumulative proteinuria. Thus pretreatment with eplerenone or enalapril is effective in reducing daily and cumulative protein excretion and preservation of nephrin/podocin. More profound antiproteinuric effects were obtained when enalapril and eplerenone were combined.

Download full-text PDF

Source
http://dx.doi.org/10.1152/ajprenal.00524.2007DOI Listing

Publication Analysis

Top Keywords

eplerenone combined
16
mg/day 0001
16
0001 cumulative
16
cumulative proteinuria
16
+/-
13
antiproteinuric effects
12
protein excretion
12
95857 +/-
12
+/- 567
12
mg/6 0001
12

Similar Publications

The mineralocorticoid receptor (MR) is a nuclear transcription factor that plays a critical role in regulating fluid, electrolytes, blood pressure, and hemodynamic stability. In conditions such as chronic kidney disease (CKD) and heart failure (HF), MR overactivation leads to increased salt and water retention, inflammatory and fibrotic gene expression, and organ injury. The MR is essential for transcriptional regulation and is implicated in metabolic, proinflammatory, and pro-fibrotic pathways.

View Article and Find Full Text PDF

Aldosterone synthase inhibitors: a potential revival for treatment of renal and cardiovascular diseases.

J Clin Endocrinol Metab

December 2024

Université Paris Cité, INSERM CIC1418, 75015 Paris, France; Hypertension Department, AP-HP, Hôpital, Georges-Pompidou, 75015 Paris, France.

Inappropriate aldosterone excess plays a key role in the pathophysiology of various cardiovascular, endocrine and renal diseases. Mineralocorticoid receptor (MR) antagonists (MRAs) such as spironolactone block of the harmful effects of aldosterone and are recommended treatment in these various conditions. However, the sexual adverse effects of spironolactone due to its lack of specificity for the MR and the risk of hyperkalemia in patients with decreased renal function, limit its use.

View Article and Find Full Text PDF
Article Synopsis
  • Hyperaldosteronism causes severe hypertension, and GPER1 may play a role as a receptor for aldosterone.
  • The study tested GPER1's effects on aldosterone-induced hypertension and inflammation using GPER1-knockout and wild-type mice in various treatment groups.
  • Results showed that GPER1 deficiency reduced blood pressure and inflammatory markers, suggesting GPER1 could be a target for treatments in cases where mineralocorticoid receptor antagonists are insufficient.
View Article and Find Full Text PDF

Therapies for Central Serous Chorioretinopathy: A Report by the American Academy of Ophthalmology.

Ophthalmology

October 2024

Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia; Department of Ophthalmology, Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska.

Purpose: To assess the safety and efficacy of the multiple therapeutic modalities for the treatment of central serous chorioretinopathy (CSCR).

Methods: A literature search of English-language studies in the PubMed database with no date restrictions was last conducted in May 2024. The combined searches yielded 612 citations, 31 of which were selected for full-text review and for inclusion in this assessment.

View Article and Find Full Text PDF
Article Synopsis
  • - Patients with chronic kidney disease (CKD) are at increased risk for heart-related issues, and medications like SGLT2 inhibitors (Dapagliflozin) and MRAs (Eplerenone) can help with cardiovascular problems, especially in diabetic cases.
  • - A study tested the effects of Dapagliflozin and Eplerenone together on heart and kidney functions in rats with non-diabetic CKD, revealing that both drugs reduced kidney fibrosis and improved heart pressure and perfusion.
  • - The combined treatment of Dapagliflozin and Eplerenone not only improved heart function but also showed a synergetic effect in reducing heart muscle damage compared to using each drug alone.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!